GCC Biopsy Devices Market to Reach US$ 72.4 Million by 2032, Accelerated by Rising Incidence of Chronic Diseases

As per the latest report by IMARC Group, titled "GCC Biopsy Devices Market Report by Procedure Type (Surgical Biopsy, Needle Biopsy), Product (Biopsy Guidance Systems, Needle Based Biopsy Guns, Biopsy Needles, Biopsy Forceps, and Others), Application (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy, and Others), Guidance Technique (Ultrasound-guided Biopsy, Stereotactic-guided Biopsy, MRI-guided Biopsy, and Others), End User (Hospitals and Clinics, Academic and Research Institutes, and Others), and Country 2024-2032," the GCC biopsy devices market size reached US$ 46.2 Million in 2023. Biopsy devices are medical equipment used to extract sample cells and tissues from an organ. Needles, localization wires, biopsy guns, and forceps are some of the commonly used biopsy devices. They are manufactured using high-quality materials such as stainless steel, titanium, or disposable plastic components. These devices undergo strict quality control measures to ensure their safety and reliability. They are used in minimally invasive (MI) procedures to reduce patient discomfort and recovery time. Biopsy devices are also used imaging technologies such as ultrasound, magnetic resonance imaging (MRI), or computerized tomography (CT) scan guidance to assist in accurate targeting of the biopsy site. Currently, there are several types of biopsy devices available in the GCC market, each catering to specific medical requirements, including fine-needle aspiration (FNA) biopsy devices, core needle biopsy, and vacuum-assisted biopsy devices.

GCC Biopsy Devices Market Trends:

The GCC biopsy devices market is being accelerated by various factors, including the rising incidence of chronic diseases, such as cancer. Moreover, the expanding healthcare infrastructure, including hospitals, diagnostic centers, and research institutions, and the growing awareness among patients and healthcare providers about the benefits of early detection and personalized treatment are propelling the market growth. Furthermore, rapid advancements in imaging technologies and their integration with biopsy devices have significantly improved the accuracy and success rates of biopsies, which is creating a positive outlook for the market. Moreover, the availability of real-time imaging guidance, such as ultrasound or MRI, and the continuous development of novel biopsy techniques, such as liquid biopsies, which analyze circulating tumor cells or genetic material, are driving the market growth. Besides this, the increasing geriatric population, which is more susceptible to various diseases, and the growing preference for minimally invasive (MI) procedures are providing an impetus to the market growth. Additionally, governments of various nations are undertaking initiatives and offering favorable reimbursement policies, which is boosting the market growth. In line with this, key players are introducing new product variants with better visualization and guidance due to the escalating demand for precision medicine and personalized treatment approaches, which is supporting the market growth. Other factors, such as the integration of artificial intelligence (AI) and machine learning (ML) algorithms in biopsy devices, the burgeoning healthcare expenditure, the rapid expansion of the private healthcare sector and medical tourism, and increasing research and development (R&D) activities to enhance the efficacy of biopsy devices, are influencing the market growth. Looking forward, the market value is projected to reach US$ 72.4 Million by 2032, expanding at a CAGR of 4.98% during 2024-2032.

Market Summary: 

• By the procedure type, the market is bifurcated into surgical biopsy and needle biopsy.
• Based on the product, the market is divided into biopsy guidance systems, needle-based biopsy guns, biopsy needles, biopsy forceps, and others.
• On the basis of the application, the market is segregated into breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others.
• By the guidance technique, the market is categorized into ultrasound-guided biopsy, stereotactic-guided biopsy, MRI-guided biopsy, and others.
• Based on the end user, the market is segmented into hospitals and clinics, academic and research institutes, and others.
• On the basis of the country, the market has been categorized into Saudi Arabia, UAE, Qatar, Oman, Kuwait, and Bahrain.
• The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Scope:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800